


## Curriculum Vitae

<b>Name</b>	<b>Sun-Young Kong</b>	
<b>Current Position &amp; Affiliation</b>	<b>Chief, Department of Laboratory Medicine, National Cancer Center</b>	
<b>Country</b>	<b>Korea, South</b>	

### Educational Background and Professional Qualifications

2002 - 2005 Ph. D. Sungkyunkwan University Graduate School of Medicine  
 1998 - 2001 M.S. Ewha Womans University Graduate School of Medicine  
 1991 - 1997 M.D. Ewha Womans University College of Medicine

### Professional Experience

2018.01- Present Chief, Department of Laboratory Medicine,  
National Cancer Center

2017.03 - 2019.01 Chief, Flow Cytometry Unit, National Cancer Center

2017.03 - 2017.11 Chief, Translational Research Branch, National Cancer Center

2014.03 - Present Professor, Department of System Cancer Science,  
Graduate School of Cancer Science & Policy

2013.03 - 2017.02 Chief, Translational Epidemiology Branch,  
National Cancer Center

2009.09 - 2011.08 Dana-Farber Cancer Institute

2009.02 - 2012.01 Senior Scientist, Hematologic Malignancies Branch,  
National Cancer Center

2005.03 - 2009.01 Associate Scientist, Hematologic Malignancies Branch,  
National Cancer Center

2005.03 - Present Specialist, Department of Laboratory Medicine,  
National Cancer Center

2003.06 - 2005.02 Clinical Fellowship, National Cancer Center

2002.03 - 2003.05 Clinical Fellowship, Samsung Medical Center

1998.03 - 2002.02 Residency, Samsung Medical Center

1997.03 - 1998.02 Internship, Samsung Medical Center

## Professional Organizations

2015 ~ Present Korea Genome Organization  
2013 ~ Present Korean Society for Genetic Diagnostics  
2013 ~ Present Korean Society for Laboratory Hematology  
2012 ~ Present Korean Society of Medical Oncology  
2003 ~ Present Korean Society for Laboratory Medicine  
2006 ~ Present Korean Cancer Association  
2007 ~ Present Korean Society of Hematology

## Main Scientific Publications

2018 Prognostic implications of multiplex detection of KRAS mutations in cell-free DNA from patients with pancreatic ductal adenocarcinoma: Clinical chemistry. 64(4):726~734 (IF : 8.636)  
2019 Integrative In Vivo Drug Testing Using Gene Expression Signature and Patient-Derived Xenografts from Treatment-Refractory HER2 Positive and Triple-Negative Subtypes of Breast Cancer: CANCERS. 11(4):E574~E574 (IF : 6.162)  
2019 Integrative molecular profiling identifies a novel cluster of estrogen receptor-positive breast cancer in very young women: cancer science. 110(5):1760~1770 (IF : 4.751)  
2020 Exon splicing analysis of intronic variants in multigene cancer panel testing for hereditary breast/ovarian cancer: CANCER SCIENCE. 111(10):3912~3925 (IF : 4.966)  
2018 Differences in attitudes toward genetic testing among the public, patients, and health-care professionals in Korea: European journal of human genetics. 26(10):1432~1440 (IF : 3.636)